Pacira BioSciences to Announce Financial Results
Pacira BioSciences, Inc. (NASDAQ: PCRX), a pioneering company in non-opioid pain management therapies, is set to report its third-quarter financial performance on Thursday, November 6, 2025, after the U.S. markets close. This anticipated announcement reflects the company's ongoing commitment to enhancing patient care through innovative solutions.
Live Conference Call and Webcast Details
Following the financial results release, the company will conduct a live conference call at 4:30 p.m. ET, allowing stakeholders and interested parties the opportunity to gain insights directly from the management team. There will also be a webcast available for those who prefer an online format.
Participation and Access to Information
For those interested in participating in the Q&A session post-announcement, pre-registration is encouraged. All registrants will be provided with dial-in information and a unique PIN for access. Moreover, a webcast of the conference call will be available for playback on the company website for about two weeks, ensuring that all interested individuals can remain informed.
Overview of Pacira BioSciences
Pacira is at the forefront of providing innovative non-opioid therapies to improve patient outcomes. The company proudly offers three main non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), which serves as a long-acting local analgesic; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), designed for managing osteoarthritis knee pain; and ioveraº, a cutting-edge device that provides immediate, effective, drug-free pain control. Pacira is also advancing its research program with PCRX-201, a novel gene therapy aimed at treating prevalent conditions such as osteoarthritis.
The Importance of Non-Opioid Treatments
The need for non-opioid alternatives to manage pain has never been more crucial, especially in light of the growing public health crisis surrounding opioid prescriptions. Pacira's innovative approach aims to transform the standard of care for pain management, providing safer options for healthcare providers and patients alike.
Investor Relations Contact
For investors seeking further information about the upcoming announcement or the company in general, Pacira BioSciences provides a direct line to investor relations. Christian Pedetti can be contacted at (973) 254-4387 or via email at Christian.Pedetti@pacira.com. Engaging with investor relations professionals provides clarity on the company's strategic direction and future opportunities.
Frequently Asked Questions
What date will Pacira report its Q3 financial results?
Pacira BioSciences plans to report its Q3 financial results on November 6, 2025.
How can I participate in the live conference call?
Interested participants should pre-register to receive dial-in information for the live conference call on the release date.
What types of therapies does Pacira offer?
Pacira offers non-opioid therapies such as EXPAREL, ZILRETTA, and ioveraº, focusing on pain management.
Who can I contact for investor inquiries at Pacira?
You can reach Christian Pedetti at (973) 254-4387 or email Christian.Pedetti@pacira.com for any investor-related questions.
Is there a replay available for the conference call?
Yes, a replay of the conference call will be accessible on Pacira's website for approximately two weeks following the event.